Clinical Trial Update: Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial [Phase 2]

View source ↗

Summary

This Phase 2 trial (PROMOTE-FL) evaluates pirtobrutinib in combination with mosunetuzumab for relapsed/refractory follicular lymphoma and is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: University of Washington | Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Status: RECRUITING